Pharmaceuticals News and Research

RSS

Modulation of cerebral endocannabinoid system may help treat Fragile X chromosome syndrome

Researchers at the University of the Basque Country (UPV/EHU) and the Achucarro neurosciences centre have discovered a new therapy for the fragile X chromosome syndrome. This new therapy proposes the modulation of the cerebral endocannabinoid system in order to ameliorate the symptoms of the disease.

11 Apr 2013

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.

11 Apr 2013

TSRI scientists shed light on major toxic mechanisms of Alzheimer's disease

Scientists at The Scripps Research Institute have shed light on one of the major toxic mechanisms of Alzheimer's disease. The discoveries could lead to a much better understanding of the Alzheimer's process and how to prevent it.

11 Apr 2013

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

DelMar Pharmaceuticals, Inc. today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor.

11 Apr 2013

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia.

11 Apr 2013

Viewpoints: Obama budget doesn't address 'heart of our debt crisis;' Attention deficit crisis; Insurer sings a different song when consumer owes it money

The U.S. has huge budget challenges. And for the first time in years, we will have three budget proposals to carefully consider -- instead of speeches and talking points.

11 Apr 2013

Data on PV-10 combination therapy presented at AACR Annual Meeting

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented data on PV-10 combination therapy today at the American Association for Cancer Research Annual Meeting in Washington, DC.

11 Apr 2013

Doctors don't receive information about harmful effects of medicines during promotional visits

The majority of family doctors receive little or no information about harmful effects of medicines when visited by drug company representatives, according to an international study involving Canadian, U.S. and French physicians.

11 Apr 2013

Tiny proteins prevent bacterial gene transcription

In the search for new antibiotics, researchers are taking an unusual approach: They are developing peptides, short chains of protein building blocks that effectively inhibit a key enzyme of bacterial metabolism.

10 Apr 2013

Five Japanese drug makers form PPP to accelerate development of drugs, vaccines for infectious diseases

"Five Japanese pharmaceutical giants are teaming up with the Bill & Melinda Gates Foundation and Japan's government to develop new medicines, vaccines, and diagnostics for infectious diseases in developing countries," GENNews reports (4/8).

10 Apr 2013

New research shows promise in creating chemical reactions necessary for pharmaceutical companies

Shaken, not stirred, is the essence of new research that's showing promise in creating the chemical reactions necessary for industries such as pharmaceutical companies, but eliminating the resulting waste from traditional methods.

10 Apr 2013

REVEAL trial: VASCAZEN meets primary endpoint

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, is pleased to announce that VASCAZEN met its primary endpoint in the REVEAL trial.

10 Apr 2013

Boehringer Ingelheim's STARTVerso 1 Phase 3 hepatitis C data to be presented at EASL Congress

Boehringer Ingelheim today announced that data from its pivotal STARTVerso 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress 2013: 48th Annual Meeting of the European Association for the Study of the Liver, taking place from April 24-28 in Amsterdam, The Netherlands.

10 Apr 2013

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces top-line results from REFRESH, a phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

10 Apr 2013

Bayer HealthCare and German Cancer Research Center to extend strategic alliance in search of novel cancer therapeutics

Bayer HealthCare (Bayer) and the German Cancer Research Center (DKFZ) will extend their successful strategic research alliance in search of novel cancer therapeutics by focusing their activities also on the field of immunotherapy. Immunotherapies are a promising approach to treat cancer with the aim to selectively reactivate the body's own immune system so that it attacks tumor cells.

10 Apr 2013

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.

10 Apr 2013

Cell>Point reports encouraging results from Phase 2a cardiovascular clinical study of 99mTc-EC-G

Cell>Point announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri.

10 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Most Americans concerned about misuse of pain medication to treat chronic pain

A new national public opinion poll commissioned by Research!America shows only 18% of respondents believe chronic pain is a major health problem, even though a majority of Americans (63%) say they know someone who experienced pain so severe that they sought prescription medicines to treat it.

10 Apr 2013

Absorption Systems, Synerzys Lifecare partner to expand use of Biopharmaceutics Classification System

The preclinical contract research organization Absorption Systems, a global leader in pharmacokinetic testing of drugs, announces that it has entered into a partnership with the Indian pharmaceutical consulting firm Synerzys Lifecare Pvt Ltd.

9 Apr 2013

Pharmaceuticals News and Research

Modulation of cerebral endocannabinoid system may help treat Fragile X chromosome syndrome

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

TSRI scientists shed light on major toxic mechanisms of Alzheimer's disease

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

BioLineRx gets regulatory approvals in US to start BL-8040 Phase IIa trial for treatment of AML

Viewpoints: Obama budget doesn't address 'heart of our debt crisis;' Attention deficit crisis; Insurer sings a different song when consumer owes it money

Data on PV-10 combination therapy presented at AACR Annual Meeting

Doctors don't receive information about harmful effects of medicines during promotional visits

Tiny proteins prevent bacterial gene transcription

Five Japanese drug makers form PPP to accelerate development of drugs, vaccines for infectious diseases

New research shows promise in creating chemical reactions necessary for pharmaceutical companies

REVEAL trial: VASCAZEN meets primary endpoint

Boehringer Ingelheim's STARTVerso 1 Phase 3 hepatitis C data to be presented at EASL Congress

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Bayer HealthCare and German Cancer Research Center to extend strategic alliance in search of novel cancer therapeutics

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Cell>Point reports encouraging results from Phase 2a cardiovascular clinical study of 99mTc-EC-G

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

Most Americans concerned about misuse of pain medication to treat chronic pain

Absorption Systems, Synerzys Lifecare partner to expand use of Biopharmaceutics Classification System

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence